Pharma BD Deal Intelligence
AstraZeneca received an exclusive global license to research, develop and commercialize LM-305, a preclinical GPRC5D-targeting ADC. LaNova received up to $55M in upfront/near-term payments plus up to $545M in development/commercial milestones, with tiered royalties on global net sales. Following the license, AstraZeneca renamed the asset AZD0305 and advanced it from preclinical into an AstraZeneca-sponsored modular Phase I/II dose-escalation study in relapsed/refractory multiple myeloma (NCT06106945; study start December 2023), with early dose-escalation data presented at ASH 2024 — validating the deal thesis of in-licensing a preclinical GPRC5D ADC for clinical advancement. (LaNova's own earlier LM-305 trial, NCT05647512, was withdrawn in November 2023 with no enrollment, superseded by AstraZeneca's program.) LaNova Medicines is separately being acquired by Sino Biopharmaceutical (announced July 2025, up to ~$950.9M); the AstraZeneca LM-305 license remains intact.